IRCT20200128046294N3RecruitingPhase 1
Safety study of Sofosbuvir 800mg and Daclatasvir 120mg in adult outpatients with COVID-19
Trial Snapshot
- Phase
- Phase 1
- Status
- Recruiting
- Enrollment
- 50
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 years to no limit (—)
- Sex
- All
Inclusion Criteria
- •Age higher than 18 years old
- •Diagnosis of COVID 19
- •Patients that do not need to be admitted in hospital
Exclusion Criteria
- •Patients without consent form
- •Patients that can not come for follow-up
- •Pregnancy , breast feeding
- •Renal insufficiency with eGFR less than 30 , or serum creatinin higher than 2.5 mg/dl in male and 2 mg/dl in female
- •Heart rate less than 50/ min
- •Hepatitis B infection
- •Amiodarone and /or Warfarin consumption
Investigators
Similar Trials
Completed
Not Applicable
Safety And Effectiveness Of Sofosbuvir And Daclatasvir In Patients Who Have Thalassemia With Hepatitis C Virus Infection And Who Are 6 years To 18 Years OldCTRI/2020/06/025910Riten Kumar Samadder70
Completed
Phase 3
Evaluation of the effect of sofosbuvir/daclatasvir in COVID-19 patientsCOVID-19.U07.1COVID-19IRCT20200624047908N1Abadan University of Medical Sciences1,000
Completed
Phase 2
Comparison of the effect of Sofosbuvir + Daclatasvir (Sovodac) and Ribavirin in Covid-19COVID-19.2019-nCOV diseaseU07.1IRCT20200324046850N2Abadan University of Medical Sciences62
Recruiting
Phase 2
Efficacy & Safety of Sofosbuvir/Daclatasvir treatment in COVID-19: A randomized, controlled studyCOVID-19SARS-nCoV-2 infectionDRKS00022203PHARCO CORPORATE90
Completed
Not Applicable
Sofosbuvir and Daclatasvir for treatment of Hepatitis-C in patients undergoing hemodialysis.IRCT20170614034526N3Jinnah Hospital, Lahore36